Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
2.111
-0.059 (-2.71%)
Jan 14, 2025, 4:00 PM EST - Market closed
Inventiva Employees
As of December 31, 2023, Inventiva had 123 total employees, including 120 full-time and 3 part-time employees. The number of employees increased by 10 or 8.85% compared to the previous year.
Employees
123
Change (1Y)
10
Growth (1Y)
8.85%
Revenue / Employee
$167,907
Profits / Employee
-$907,576
Market Cap
199.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
IVA News
- 4 weeks ago - Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million - GlobeNewsWire
- 4 weeks ago - Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024 - GlobeNewsWire
- 7 weeks ago - Inventiva reports 2024 Third Quarter Financial Information¹ - GlobeNewsWire
- 7 weeks ago - Combined General Meeting of December 11, 2024 - Availability of the preparatory documents - GlobeNewsWire
- 2 months ago - Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams - Business Wire
- 2 months ago - Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session - GlobeNewsWire
- 2 months ago - Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH - GlobeNewsWire